Report Contents
Market Overview
The global COVID testing kits market is generating an estimated USD 17.20 Billion in revenue in 2025 and is projected to expand steadily at a compound annual growth rate of 5.80% from 2026 to 2032. This growth trajectory reflects ongoing demand from hospital networks, public health agencies, and at-home diagnostics, even as emergency phases of the pandemic recede. Converging trends in respiratory syndromic panels, point-of-care molecular diagnostics, and digital health integration are broadening the market’s scope beyond crisis response into routine infectious disease management and pandemic preparedness.
Success in this evolving landscape hinges on strategic imperatives such as scalable manufacturing, country-level localization of regulatory and reimbursement strategies, and deep technological integration with data platforms and telehealth ecosystems. This report is positioned as an essential strategic tool, providing forward-looking analysis to guide investment decisions, partnership models, and product roadmaps amid shifting clinical protocols, competitive disruptions, and global health security priorities.
Market Growth Timeline (USD Billion)
Source: Secondary Information and ReportMines Research Team - 2026
Market Segmentation
The COVID Testing Kits Market analysis has been structured and segmented according to type, application, geographic region and key competitors to provide a comprehensive view of the industry landscape.
Key Product Application Covered
Key Product Types Covered
Key Companies Covered
By Type
The Global COVID Testing Kits Market is primarily segmented into several key types, each designed to address specific operational demands and performance criteria.
-
Rapid antigen test kits:
Rapid antigen test kits hold a substantial share of the COVID Testing Kits Market because they enable point-of-care diagnostics with turnaround times often below fifteen to twenty minutes. These assays are widely adopted in workplaces, schools and travel checkpoints where high-frequency, decentralized screening is required to manage transmission risks in real time. Their lower per-test cost compared with molecular assays makes them a preferred option for large-scale population screening in both developed and resource-constrained healthcare systems.
The primary competitive advantage of rapid antigen test kits lies in their operational simplicity and minimal equipment requirement, which can reduce testing workflow costs by an estimated thirty to fifty percent relative to laboratory-based RT-PCR workflows. While their clinical sensitivity can be in the seventy to ninety percent range for high viral load cases, their ease of use and scalability enable very high daily throughput when deployed in community testing programs. Growth is currently fueled by employer-driven routine screening protocols and government-led surveillance campaigns that prioritize speed and logistical flexibility over maximum analytical sensitivity.
-
RT-PCR test kits:
RT-PCR test kits remain the gold-standard segment in the Global COVID Testing Kits Market, providing the highest analytical sensitivity and specificity for clinical diagnosis. These kits dominate hospital laboratories, reference laboratories and centralized testing centers where confirmatory testing is required for treatment decisions, hospital admissions and public health reporting. The segment continues to account for a significant portion of total testing revenue because healthcare providers rely on RT-PCR for case confirmation and variant monitoring.
The competitive advantage of RT-PCR kits lies in their ability to detect viral RNA with sensitivity frequently exceeding ninety-five percent, even at relatively low viral loads, which reduces the rate of false negatives compared with antigen-based approaches. Modern RT-PCR platforms can process hundreds to thousands of samples per day per instrument, supporting high-throughput workflows necessary for national testing programs. Growth is primarily driven by the ongoing need for definitive diagnosis, regulatory requirements for confirmatory testing in many jurisdictions and the integration of RT-PCR systems into broader molecular diagnostics platforms that also address other infectious diseases.
-
Isothermal amplification test kits:
Isothermal amplification test kits represent an emerging, technology-driven segment that aims to combine the sensitivity of molecular diagnostics with the speed and simplicity of near-point-of-care formats. These kits typically operate at a constant temperature, which removes the need for complex thermal cycling equipment and allows for more compact and cost-efficient analyzers. As healthcare providers seek molecular accuracy outside traditional laboratory walls, isothermal assays are gaining traction in urgent care centers, outpatient clinics and decentralized testing hubs.
The key competitive advantage of isothermal amplification kits is their ability to produce results in approximately fifteen to thirty minutes while achieving sensitivity levels that can approach eighty-five to ninety-five percent, depending on the platform and use case. By reducing equipment complexity and energy requirements, these systems can lower capital expenditure for molecular testing infrastructure by a significant portion compared with full-scale RT-PCR laboratories. Their growth is catalyzed by technological innovation in nucleic acid amplification methods and by health system strategies focused on rapid, near-patient molecular testing that shortens clinical decision-making times.
-
Serology and antibody test kits:
Serology and antibody test kits occupy a distinct niche in the COVID Testing Kits Market by assessing immune response rather than acute infection. These assays are widely used in epidemiological studies, vaccine efficacy monitoring and longitudinal cohort research to estimate population-level exposure and immunity. Clinical laboratories and research institutions rely on these tests to support public health decisions related to booster campaigns and long-term disease surveillance.
The competitive advantage of serology kits stems from their ability to process high sample volumes using automated immunoassay analyzers, with many systems capable of handling several hundred tests per hour with high reproducibility. While they are not suited for frontline diagnostic decisions on active infection, they provide critical quantitative or semi-quantitative metrics on antibody titers that no other kit type offers. Growth in this segment is driven by continued vaccine rollouts, the need to evaluate waning immunity over time and expanding research on hybrid immunity that requires consistent antibody measurement across large populations.
-
Combination respiratory panel test kits:
Combination respiratory panel test kits have become increasingly important as healthcare providers seek to differentiate COVID-19 from other respiratory pathogens such as influenza and respiratory syncytial virus within a single test. These multiplex molecular panels are predominantly deployed in hospital emergency departments and intensive care units where rapid, comprehensive respiratory diagnostics directly influence isolation measures and therapeutic choices. As seasonal respiratory virus activity normalizes, demand for multi-pathogen panels is rising relative to single-target COVID-only tests.
The main competitive advantage of these panels is their ability to detect multiple viruses and sometimes bacterial pathogens simultaneously, which can reduce total testing time and reagent use per patient by a significant portion compared with running several separate assays. Many platforms can deliver results in under one to two hours while maintaining molecular-level sensitivity for each target, improving diagnostic yield and reducing unnecessary antibiotic prescriptions. Their growth is driven by a clinical shift toward syndromic testing strategies, reimbursement support for multiplex assays in many health systems and hospital policies that favor comprehensive respiratory diagnostics to optimize bed management and infection control.
-
Self-test and over-the-counter COVID test kits:
Self-test and over-the-counter COVID test kits form one of the most consumer-centric and rapidly expanding segments of the market, enabling individuals to perform testing at home without professional supervision. These kits are widely distributed through pharmacies, retail channels and e-commerce platforms, which allows large-scale access during infection surges and travel peaks. Their convenience and direct-to-consumer model have shifted a substantial portion of routine screening away from clinical facilities and into households.
The competitive advantage of self-test kits lies in their highly simplified workflows and clear instructions that enable non-professionals to obtain results, usually within fifteen to thirty minutes, using minimally invasive sample collection. By eliminating the need for a clinical appointment and reducing associated administrative overhead, these tests can lower overall testing-related costs for payers and consumers by a notable margin. Growth is primarily fueled by regulatory support for at-home testing, increased health literacy among consumers and integration of app-based result reporting that links self-tests to digital health passports and employer compliance platforms.
Market By Region
The global COVID Testing Kits market demonstrates distinct regional dynamics, with performance and growth potential varying significantly across the world's major economic zones.
The analysis will cover the following key regions: North America, Europe, Asia-Pacific, Japan, Korea, China, USA.
-
North America:
North America holds a strategically important position in the global COVID Testing Kits market due to its advanced healthcare infrastructure, strong diagnostics manufacturers, and rapid adoption of molecular and antigen-based assays. The United States and Canada act as primary demand centers, driven by extensive screening programs, employer-led testing, and high insurance coverage. The region accounts for a significant portion of global revenue, providing a mature and relatively stable demand base that underpins global supply chain planning and capacity utilization.
Untapped potential remains in community health centers, smaller private practices, and rural hospital networks where testing capabilities still lag urban academic medical centers. Opportunities arise in decentralized point-of-care platforms, home self-test kits, and integrated digital reporting tools that can support surveillance and outbreak management. Key challenges include reimbursement pressure, test commoditization, and managing high expectations for accuracy and turnaround times while maintaining cost efficiency in large-scale procurement contracts.
-
Europe:
Europe represents a critical regional hub for the COVID Testing Kits industry, characterized by strong regulatory oversight, established diagnostics companies, and coordinated public health initiatives. Major markets such as Germany, the United Kingdom, France, Italy, and Spain drive regional consumption, supported by national screening strategies and centralized procurement frameworks. Europe contributes a substantial share of global demand, functioning as a relatively mature market where replacement demand and platform upgrades are increasingly important growth drivers.
Significant untapped potential exists in cross-border standardization of testing protocols, expanded use of rapid antigen assays in primary care, and better integration of testing with electronic health records. Eastern and Southern European countries still present growth opportunities where laboratory infrastructure and home-testing penetration remain below Western European levels. Challenges include budget-constrained health systems, heterogeneous reimbursement policies, and increasing emphasis on local manufacturing resilience to reduce dependence on extra-regional suppliers.
-
Asia-Pacific:
The broader Asia-Pacific region, excluding Japan, Korea, and China as separate focal markets, is a high-growth arena for COVID Testing Kits, driven by large and diverse populations, rising healthcare expenditure, and expanding laboratory networks. Countries such as India, Australia, Singapore, and Southeast Asian economies serve as core demand nodes, combining centralized reference laboratories with rapidly growing point-of-care testing. Asia-Pacific contributes a growing share of global volume, particularly for cost-sensitive rapid test kits and high-throughput PCR solutions catering to mass screening.
Untapped potential is substantial in rural and semi-urban areas, where limited lab infrastructure and workforce shortages constrain access to timely diagnostics. Opportunities lie in affordable, rugged point-of-care platforms, bundled reagent and instrument solutions, and public-private partnerships that expand screening in primary health centers. Key challenges include pricing pressure, uneven regulatory frameworks, and supply chain vulnerabilities during infection surges, which can disrupt distribution to archipelagic and remote geographies across the region.
-
Japan:
Japan plays a specialized yet influential role in the global COVID Testing Kits market, leveraging its advanced medical technology base, strong local diagnostics manufacturers, and high-quality clinical laboratory standards. The country maintains robust demand for high-precision PCR systems, automated analyzers, and carefully validated antigen tests deployed across hospitals and sophisticated clinic networks. Japan’s market share is moderate globally but strategically important as a reference market for premium, high-sensitivity testing platforms and stringent quality benchmarks.
There is notable untapped potential in expanding rapid self-testing adoption among consumers, enhancing testing penetration in smaller clinics, and integrating test data with digital health platforms for real-time epidemiological monitoring. Aging demographics and a strong focus on infection control in long-term care facilities also create ongoing demand. Challenges include conservative regulatory pathways, a preference for domestically proven technologies, and cost-containment pressures within the national health insurance system that influence pricing and procurement decisions.
-
Korea:
Korea holds a strategic position in the COVID Testing Kits market as both a major manufacturing base and an innovation hub for rapid and molecular diagnostics. The country’s rapid scale-up of PCR testing capacity and export-oriented test kit production positioned it as a key global supplier early in the pandemic. Domestically, high health literacy and strong governmental coordination support consistent testing volumes across hospitals, screening centers, and occupational health programs.
Untapped potential lies in further international expansion of Korean test kit brands into emerging markets, along with diversification into multiplex respiratory panels and integrated PCR platforms suitable for mid-tier laboratories. Within Korea, opportunities remain in home-based self-testing, digital result platforms, and expanded use of rapid tests in schools and workplaces. Key challenges involve intense global competition, regulatory differences across export markets, and the need to sustain demand as case volumes stabilize and some governments scale back large centralized testing programs.
-
China:
China represents one of the largest and most dynamic markets for COVID Testing Kits, underpinned by its extensive population, large-scale mass testing campaigns, and strong domestic manufacturing ecosystem. Major urban centers such as Beijing, Shanghai, Guangzhou, and Shenzhen anchor demand, supported by expansive hospital networks and commercial laboratories. China commands a significant share of global volume, particularly in high-throughput PCR testing and competitively priced rapid antigen kits that are also exported to multiple regions.
Considerable untapped potential remains in lower-tier cities, rural counties, and community health centers where consistent access to high-quality diagnostics is still evolving. Opportunities include scalable point-of-care platforms, mobile testing units, and integration of testing data with national health codes and digital surveillance systems. Challenges involve regulatory tightening on export quality standards, price erosion in domestic tenders, and the ongoing transition from emergency procurement to more routine, demand-driven purchasing patterns in public hospitals and health authorities.
-
USA:
The USA functions as the single most influential national market within the global COVID Testing Kits industry, combining very high per-capita testing capacity with a diverse mix of public, private, and retail healthcare channels. Large reference laboratories, integrated delivery networks, pharmacy chains, and direct-to-consumer brands all contribute to sustained testing volumes across PCR, rapid antigen, and at-home self-test segments. The USA accounts for a major share of global revenue and sets important benchmarks in product innovation, reimbursement models, and healthcare payer engagement.
Untapped potential persists in underserved communities, rural counties, and low-income urban areas where access to reliable testing remains inconsistent. There are growth opportunities in telehealth-integrated home testing, workplace and university surveillance programs, and multiplex panels that combine COVID with influenza and RSV diagnostics. Key challenges include reimbursement volatility as emergency funding winds down, heightened regulatory scrutiny for over-the-counter tests, and competitive pressure driving consolidation among kit manufacturers and distribution partners.
Market By Company
The COVID Testing Kits market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.
-
Abbott Laboratories:
Abbott Laboratories holds a leading position in the COVID Testing Kits market owing to its broad portfolio of rapid antigen tests, molecular assays, and high-throughput systems deployed across hospitals, urgent care centers, and decentralized settings. The company capitalized on its global distribution network and existing point-of-care platforms to scale COVID test availability rapidly in both mature and emerging diagnostics markets.
In 2025, Abbott’s COVID testing kits revenue is estimated at USD 2.35 billion with a market share of 13.65% . These figures indicate that Abbott is one of the largest single contributors to global COVID test kit volumes, reflecting strong brand recognition, reliable assay performance, and established procurement relationships with public health agencies and large healthcare providers.
Abbott’s strategic advantage lies in its point-of-care expertise, particularly the integration of COVID assays into its existing lateral flow and portable analyzer platforms, which simplifies logistics and training requirements for providers. The company leverages strong manufacturing scale, regulatory experience, and data connectivity solutions that enable real-time reporting of test results, thereby strengthening its competitive positioning against smaller pure-play diagnostics firms and maintaining relevance as testing protocols evolve toward more targeted, high-risk population screening.
-
F. Hoffmann-La Roche Ltd:
F. Hoffmann-La Roche Ltd plays a critical role in the COVID Testing Kits market through its strong molecular diagnostics and high-throughput laboratory systems, which support centralized testing in hospitals and reference laboratories worldwide. The company’s real-time PCR assays and fully automated analyzers have become key components of national testing infrastructures, especially in countries emphasizing high-volume, laboratory-based surveillance.
For 2025, Roche’s COVID testing kits revenue is estimated at USD 2.10 billion with a market share of 12.21% . This performance underscores its status as a top-tier diagnostics provider capable of delivering reliable, high-sensitivity assays at scale, and reflects significant repeat purchasing by hospital systems, public health labs, and integrated delivery networks.
Roche’s strategic differentiation stems from the integration of COVID testing into its broader virology and respiratory pathogen panels, allowing laboratories to run multiplex tests that detect SARS-CoV-2 alongside influenza and other respiratory viruses. Its installed base of cobas and other automated platforms, combined with strong clinical evidence and global regulatory approvals, provides a durable competitive moat as health systems rationalize testing menus and consolidate volumes onto a smaller set of trusted platforms.
-
QuidelOrtho Corporation:
QuidelOrtho Corporation is a prominent player in rapid COVID antigen testing, with strong penetration in physician offices, retail clinics, and decentralized point-of-care environments. The company built on its expertise in lateral flow immunoassays and analyzer-based rapid tests to scale COVID testing rapidly, particularly in North America and selected international markets.
In 2025, QuidelOrtho’s COVID testing kits revenue is estimated at USD 0.95 billion with a corresponding market share of 5.52% . These figures show that the company commands a meaningful share of the rapid testing segment, positioning it as a key competitor in cost-sensitive and high-throughput community testing programs.
QuidelOrtho’s competitive advantage lies in its focus on rapid turnaround and ease of use, enabling frequent testing in schools, workplaces, and pharmacies where laboratory infrastructure is limited. The company benefits from a broad installed base of point-of-care analyzers, recurring consumable demand, and the ability to bundle COVID assays with other respiratory tests, which helps stabilize utilization as pandemic-driven demand moderates and shifts toward endemic management strategies.
-
Becton, Dickinson and Company:
Becton, Dickinson and Company has established itself as a significant contributor to the COVID Testing Kits market through both point-of-care and laboratory-based diagnostic solutions. Its portfolio includes rapid antigen tests and molecular assays deployed on automated platforms that support medium-throughput testing in hospitals, clinics, and community health settings.
For 2025, BD’s COVID testing kits revenue is estimated at USD 0.88 billion and a market share of 5.12% . This combination reflects its strong but balanced presence across multiple testing settings, highlighting competitiveness in both rapid detection and confirmatory testing workflows.
BD’s strategic strengths include deep relationships with hospital laboratories, established expertise in specimen collection and consumables, and integrated diagnostic platforms that streamline sample-to-result workflows. By embedding COVID assays into its broader infectious disease testing ecosystem and leveraging its global logistics capabilities, BD maintains a differentiated position against smaller niche players and remains a preferred partner for health systems seeking standardized testing solutions at scale.
-
Thermo Fisher Scientific Inc.:
Thermo Fisher Scientific Inc. plays a pivotal role in the molecular diagnostics segment of the COVID Testing Kits market, supplying PCR-based test kits, reagents, and instruments to clinical laboratories, reference labs, and government testing programs. Its comprehensive portfolio of qPCR platforms and sample preparation systems underpins a substantial portion of high-sensitivity testing globally.
In 2025, Thermo Fisher’s COVID testing kits revenue is estimated at USD 1.40 billion with a market share of 8.13% . These figures indicate strong competitiveness in high-precision molecular testing, supported by a broad installed base and robust demand from laboratories prioritizing accuracy and throughput.
The company’s competitive differentiation arises from its end-to-end solutions that span sample collection, nucleic acid extraction, PCR amplification, and data analysis, creating high switching costs for laboratories already invested in its ecosystem. Thermo Fisher also benefits from strong R&D capabilities that enable rapid assay updates as new SARS-CoV-2 variants emerge, reinforcing confidence among regulators and clinical customers and supporting sustained utilization beyond the initial pandemic surge.
-
Siemens Healthineers AG:
Siemens Healthineers AG is an influential competitor in the COVID Testing Kits market, particularly in high-throughput immunoassay and molecular testing within hospital and reference laboratories. The company leverages its extensive installed base of analyzers to deliver SARS-CoV-2 serology and molecular solutions integrated into broader clinical chemistry and immunodiagnostics workflows.
For 2025, Siemens Healthineers’ COVID testing kits revenue is estimated at USD 1.05 billion and a market share of 6.10% . This performance reflects its strong penetration in large health systems and public sector laboratories that prioritize interoperability and consolidated testing platforms.
The company’s strategic advantage stems from its ability to embed COVID assays into multi-analyte testing panels and automated platforms that run across diverse diagnostic categories, reducing operational complexity for laboratories. Combined with advanced data analytics, connectivity solutions, and strong service support, Siemens Healthineers maintains a defensible position against single-modality competitors, particularly in regions where health systems are modernizing their diagnostics infrastructure.
-
Danaher Corporation:
Danaher Corporation impacts the COVID Testing Kits market primarily through its diagnostics subsidiaries, which provide molecular and immunoassay-based solutions for clinical laboratories and point-of-care settings. Its portfolio includes high-throughput PCR tests and rapid assays that support both centralized and decentralized testing strategies.
In 2025, Danaher’s COVID testing kits revenue is estimated at USD 1.15 billion with a market share of 6.69% . These figures illustrate the company’s solid mid-to-upper tier positioning, driven by strong demand for its molecular testing platforms and reagents.
Danaher’s competitive differentiation is rooted in its disciplined operating model, acquisition-led portfolio expansion, and continuous innovation in molecular diagnostics technology. By integrating COVID tests into versatile platforms that also run a wide range of respiratory and infectious disease assays, the company ensures recurring consumables demand and high instrument utilization, thereby protecting its share as testing volumes normalize around endemic surveillance and targeted clinical use cases.
-
bioMérieux SA:
bioMérieux SA holds a notable role in the COVID Testing Kits market with a strong emphasis on microbiology and molecular diagnostics solutions for hospital and public health laboratories. Its respiratory panels and SARS-CoV-2 specific assays are widely used in Europe and other international markets where syndromic testing has gained traction.
For 2025, bioMérieux’s COVID testing kits revenue is estimated at USD 0.70 billion and a market share of 4.08% . These metrics indicate a solid mid-tier position, especially in multiplex molecular testing and integrated respiratory diagnostics.
bioMérieux’s strategic advantage lies in its expertise in syndromic testing, enabling clinicians to detect SARS-CoV-2 alongside multiple pathogens from a single sample, which improves diagnostic efficiency and stewardship. The company leverages long-standing relationships with hospital laboratories and its reputation in infection control to sustain demand, even as pure COVID testing volumes gradually shift toward broader respiratory disease management frameworks.
-
Hologic Inc.:
Hologic Inc. is an important molecular diagnostics provider in the COVID Testing Kits market, particularly through its high-throughput Panther systems deployed in clinical and reference laboratories. These platforms have processed significant volumes of SARS-CoV-2 tests due to their automation, scalability, and compatibility with multiple assay types.
In 2025, Hologic’s COVID testing kits revenue is estimated at USD 0.82 billion with a market share of 4.77% . This performance reflects strong utilization of its installed base and continued demand from laboratories seeking efficient, high-sensitivity testing.
Hologic’s competitive edge is driven by its robust molecular assay menu, allowing laboratories to leverage Panther systems for COVID testing while also running sexually transmitted infection panels, women’s health assays, and other infectious disease tests. This multi-use platform strategy enhances customer stickiness and ensures that COVID-related consumables demand is supported by broader diagnostics utilization, reinforcing Hologic’s resilience as market dynamics shift.
-
Quest Diagnostics Incorporated:
Quest Diagnostics Incorporated plays a crucial role in the COVID Testing Kits market as a major reference laboratory and service provider rather than a pure test kit manufacturer. The company procures and uses PCR and antigen kits from multiple suppliers, integrating them into nationwide testing services for employers, health plans, and government programs in the United States.
For 2025, Quest’s revenue attributable to COVID testing kits and related services is estimated at USD 0.90 billion with an implied market share of 5.23% in the end-user consumption of COVID test kits. These values demonstrate Quest’s scale as a key channel for kit utilization and confirmatory testing within the broader diagnostics ecosystem.
Quest’s strategic advantage lies in its extensive laboratory network, digital ordering platforms, and strong relationships with employers and insurers, which enable large-scale testing programs and recurring demand. By combining logistics, sample collection, and data reporting capabilities, Quest influences procurement patterns for COVID kits and strengthens the market presence of its supplier partners, while maintaining bargaining power on pricing and test mix optimization.
-
Laboratory Corporation of America Holdings:
Laboratory Corporation of America Holdings, commonly known as Labcorp, is another leading reference laboratory that significantly shapes the COVID Testing Kits market through high-volume test processing and nationwide access points. The company uses a variety of molecular and antigen kits from multiple manufacturers, integrating them into clinical testing pathways and population screening programs.
In 2025, Labcorp’s COVID-related testing kits and service revenue is estimated at USD 0.87 billion with an implied market share of 5.06% in the consumption of COVID test kits. These figures underscore its role as a major downstream driver of demand, influencing test volumes, supplier selection, and turnaround expectations across the United States.
Labcorp’s competitive differentiation is rooted in its broad payer relationships, extensive patient service center network, and strong capabilities in clinical trial testing and real-world evidence generation. By aggregating large volumes of COVID testing data, the company supports public health surveillance and employer programs while negotiating favorable terms with kit manufacturers, reinforcing its central position in the value chain despite not being a primary kit producer.
-
GenScript Biotech Corporation:
GenScript Biotech Corporation participates in the COVID Testing Kits market primarily through its molecular and serological assay development, targeting both clinical and research use. The company has leveraged its strengths in gene synthesis and biotechnology to supply reagents, test kits, and components to laboratories and diagnostic companies worldwide.
For 2025, GenScript’s COVID testing kits revenue is estimated at USD 0.35 billion with a market share of 2.04% . This position indicates meaningful participation in niche and specialized testing segments, particularly among laboratories that value flexible assay formats and research-grade products alongside clinical diagnostics.
GenScript’s strategic advantages include strong R&D capabilities in molecular biology, the ability to rapidly customize assays, and a global distribution network serving both academic and commercial customers. By supplying components and kits that can be integrated into broader testing workflows, the company occupies a hybrid role between reagent supplier and diagnostic kit provider, granting it agility to respond to variant-driven assay updates and evolving market needs.
-
Bio-Rad Laboratories Inc.:
Bio-Rad Laboratories Inc. contributes to the COVID Testing Kits market with molecular diagnostic assays, quality control materials, and supporting laboratory instruments. Its solutions are used by clinical labs and research institutions for SARS-CoV-2 detection, assay validation, and proficiency testing.
In 2025, Bio-Rad’s COVID testing kits and related products revenue is estimated at USD 0.32 billion with a market share of 1.86% . These numbers reflect a specialized but important role, particularly in quality assurance and laboratory workflow optimization rather than mass-market consumer testing.
Bio-Rad’s competitive differentiation arises from its strong reputation in assay controls, calibration materials, and precision instruments, which are critical for ensuring the reliability and reproducibility of COVID PCR and serology testing. By focusing on supporting laboratory accuracy and regulatory compliance, the company embeds itself deeply into lab workflows and maintains demand even as test volumes shift from emergency use toward long-term routine surveillance.
-
Cepheid:
Cepheid, part of a larger diagnostics group, is a key innovator in cartridge-based molecular COVID Testing Kits designed for near-patient and decentralized laboratory use. Its GeneXpert systems enable rapid, high-sensitivity PCR testing within hospitals, emergency departments, and community settings without requiring complex laboratory infrastructure.
For 2025, Cepheid’s COVID testing kits revenue is estimated at USD 1.00 billion with a market share of 5.82% . These figures highlight its strong position in rapid molecular testing, especially in settings where clinicians require accurate results within hours for treatment and isolation decisions.
Cepheid’s strategic advantage lies in its closed-cartridge technology, which minimizes contamination risk and simplifies workflow, as well as its broad menu of infectious disease assays running on the same platform. This menu breadth drives high instrument utilization and recurring cartridge demand, ensuring that COVID assay volumes remain complemented by other test types and strengthening the company’s resilience against fluctuations in single-disease testing demand.
-
SD Biosensor Inc.:
SD Biosensor Inc. is a major global provider of rapid COVID antigen and antibody test kits, particularly well represented in emerging markets and public health screening programs. Its lateral flow assays are widely used in community testing sites, workplaces, and home testing initiatives due to their affordability and ease of use.
In 2025, SD Biosensor’s COVID testing kits revenue is estimated at USD 0.80 billion with a market share of 4.66% . This indicates a strong presence in volume-driven segments where rapid turnaround and cost-efficiency are critical decision factors.
The company’s competitive differentiation is driven by its ability to scale manufacturing, secure large tenders from governments and international organizations, and offer kits that meet diverse regulatory standards across multiple regions. By focusing on high-volume distribution and robust supply reliability, SD Biosensor has become a preferred partner for mass screening campaigns and remains well positioned as countries maintain baseline testing capacity for outbreak response and endemic monitoring.
-
OraSure Technologies Inc.:
OraSure Technologies Inc. occupies an important niche in the COVID Testing Kits market through its oral fluid-based and at-home testing solutions. The company leverages its expertise in non-invasive sample collection to offer tests that improve patient comfort and compliance, especially in self-testing and community-based programs.
For 2025, OraSure’s COVID testing kits revenue is estimated at USD 0.28 billion with a market share of 1.63% . These figures reflect a focused but strategically significant role, particularly in consumer-driven testing segments and outreach initiatives targeting populations that may avoid traditional clinical settings.
OraSure’s strategic advantage stems from user-friendly sampling technologies, strong experience in infectious disease self-testing, and partnerships with public health organizations seeking to expand access to convenient at-home diagnostics. This positioning allows the company to differentiate on patient experience and accessibility rather than solely on laboratory performance metrics, giving it a defensible niche as testing shifts from emergency response toward long-term, patient-centric models.
-
Siemens Healthineers (Fast Track Diagnostics):
Siemens Healthineers (Fast Track Diagnostics) focuses on multiplex PCR panels and respiratory pathogen solutions that include SARS-CoV-2, complementing the broader Siemens Healthineers diagnostic portfolio. Its assays are deployed in hospital and reference laboratories that require syndromic testing for patients presenting with respiratory symptoms.
In 2025, the Fast Track Diagnostics unit’s COVID-inclusive testing revenue is estimated at USD 0.26 billion with a market share of 1.51% . This reflects a specialized contribution centered on comprehensive respiratory panels rather than stand-alone COVID tests.
The unit’s competitive differentiation lies in its multiplex capabilities that detect SARS-CoV-2 alongside numerous other respiratory viruses and bacteria, improving clinical decision-making and infection control. By integrating these panels within the broader Siemens Healthineers ecosystem, Fast Track Diagnostics benefits from existing customer relationships, installed platforms, and consolidated service contracts, strengthening its role in the evolving post-pandemic respiratory diagnostics market.
-
PerkinElmer Inc.:
PerkinElmer Inc. is an established participant in the COVID Testing Kits market through its molecular diagnostics assays, sample preparation systems, and automation solutions used in high-throughput testing laboratories. The company has supported large-scale national and regional testing initiatives by providing kits and instruments capable of processing substantial daily volumes.
For 2025, PerkinElmer’s COVID testing kits revenue is estimated at USD 0.45 billion with a market share of 2.62% . These numbers indicate a meaningful role in supporting centralized laboratory testing, especially in settings where throughput and automation are key procurement criteria.
PerkinElmer’s strategic advantages include strong capabilities in sample-to-answer workflow integration, robust automation technologies, and experience working with public health laboratories on large testing contracts. By aligning COVID testing offerings with broader genomic and infectious disease platforms, the company sustains instrument utilization and reinforces its competitive position as laboratories transition from pandemic-scale surge capacity to more sustainable, long-term testing operations.
-
LumiraDx Ltd:
LumiraDx Ltd is an agile challenger in the COVID Testing Kits market, focusing on point-of-care microfluidic testing platforms that deliver rapid, lab-comparable results. Its portable analyzers and COVID assays target decentralized healthcare settings, pharmacies, and community testing programs that require both speed and analytical reliability.
In 2025, LumiraDx’s COVID testing kits revenue is estimated at USD 0.25 billion with a market share of 1.46% . This reflects a growing but still emerging position, with particular strength in innovative, technology-driven segments of the point-of-care market.
The company’s competitive differentiation comes from its microfluidic technology, which enables multiplexing and improved analytical performance compared with traditional lateral flow tests, while maintaining a compact and user-friendly format. By positioning its platform for broader chronic and acute disease testing beyond COVID, LumiraDx seeks to convert pandemic-driven deployments into long-term point-of-care ecosystems, enhancing recurring consumables revenue and expanding its clinical footprint.
-
Cue Health Inc.:
Cue Health Inc. occupies a distinctive position in the COVID Testing Kits market by offering connected, at-home molecular testing solutions that combine portable analyzers with smartphone integration. Its platform enables users to perform highly sensitive COVID tests outside of clinical settings while transmitting results digitally for personal and organizational use.
In 2025, Cue Health’s COVID testing kits revenue is estimated at USD 0.30 billion with a market share of 1.75% . These figures highlight its niche but strategically important role in the digital health and home diagnostics segment.
Cue Health’s strategic advantage is anchored in its combination of molecular accuracy, user-friendly at-home operation, and integration with digital platforms that support result tracking, telehealth connectivity, and enterprise reporting. This differentiates the company from traditional test kit manufacturers and positions it at the intersection of diagnostics and digital health, offering a scalable model that can be extended beyond COVID into broader respiratory and infectious disease testing for consumers and employers.
Key Companies Covered
Abbott Laboratories
F. Hoffmann-La Roche Ltd
QuidelOrtho Corporation
Becton, Dickinson and Company
Thermo Fisher Scientific Inc.
Siemens Healthineers AG
Danaher Corporation
bioMérieux SA
Hologic Inc.
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings
GenScript Biotech Corporation
Bio-Rad Laboratories Inc.
Cepheid
SD Biosensor Inc.
OraSure Technologies Inc.
Siemens Healthineers (Fast Track Diagnostics)
PerkinElmer Inc.
LumiraDx Ltd
Cue Health Inc.
Market By Application
The Global COVID Testing Kits Market is segmented by several key applications, each delivering distinct operational outcomes for specific industries.
-
Diagnostic testing in healthcare facilities:
Diagnostic testing in healthcare facilities represents the most clinically critical application segment, as it directly supports triage, treatment decisions and infection control in hospitals, clinics and emergency departments. The core business objective is to provide definitive diagnoses that guide patient management, allocation of isolation beds and selection of antiviral or supportive therapies. This application holds a significant share of total test volumes because nearly every symptomatic admission in many health systems is screened for COVID-19 as part of standard respiratory diagnostics.
Healthcare facilities prioritize this application because it delivers a unique operational outcome: reduced clinical uncertainty and more efficient use of scarce resources, such as intensive care unit beds and personal protective equipment. When rapid molecular or high-sensitivity antigen tests are integrated into admission workflows, many hospitals report measurable improvements in bed turnover and isolation room utilization, often shortening time-to-decision by several hours compared with off-site laboratory processing. Growth in this segment is fueled by ongoing clinical protocols that require testing for respiratory symptoms, infection control regulations and the integration of COVID-19 assays into broader respiratory diagnostic algorithms that now operate year-round.
-
At-home self-testing:
At-home self-testing focuses on empowering individuals to screen for COVID-19 without visiting a clinic, thereby reducing pressure on healthcare facilities and enabling rapid decision-making about isolation and social interactions. The primary business objective is to provide convenient, on-demand access to testing that aligns with consumer schedules and minimizes indirect costs such as time off work or travel to testing sites. This application has achieved strong market significance because a substantial portion of mild or asymptomatic cases are now identified through self-administered tests purchased from pharmacies and online platforms.
Adoption of at-home self-testing is justified by its ability to deliver immediate results and reduce dependence on centralized testing infrastructure, often allowing individuals to test and obtain results within fifteen to thirty minutes. This speed can cut effective decision latency by many hours compared with scheduling a clinic visit and waiting for laboratory results, which improves compliance with isolation recommendations and reduces workplace and household exposure. Growth is driven by regulatory authorization of over-the-counter kits, increased employer and school acceptance of self-test results and the proliferation of digital companion applications that help users interpret results and, in some cases, upload them to employer or travel platforms.
-
Occupational and workplace screening:
Occupational and workplace screening is designed to maintain business continuity and protect employee health by routinely testing workers in manufacturing plants, corporate offices, logistics hubs and other employment settings. The core objective is to minimize unplanned downtime and avoid production disruptions caused by outbreaks, especially in sectors where on-site presence is essential, such as automotive manufacturing or food processing. This application has become strategically important for employers that operate large facilities where even brief shutdowns can translate into substantial revenue losses.
Organizations adopt workplace screening because it delivers a tangible operational outcome: reduced absenteeism and lower risk of facility-wide closures, often through scheduled weekly or bi-weekly testing of targeted teams. In some documented implementations, regular screening programs help cut outbreak-related downtime by a significant portion, as infected employees are identified earlier and isolated before wider transmission occurs. Growth in this segment is propelled by corporate health and safety policies, insurance and liability considerations and the availability of cost-effective rapid antigen and pooled molecular testing strategies that make ongoing surveillance economically viable for medium and large employers.
-
Travel and border control screening:
Travel and border control screening focuses on managing cross-border infection risks by testing passengers at airports, seaports and land checkpoints. The business objective is to maintain mobility and tourism revenue while controlling the importation of new cases and variants into a country or region. This application has high strategic importance for national governments and transportation providers, as it underpins travel corridor agreements and supports public confidence in international and domestic travel.
Adoption of testing in this context is justified by its operational outcome of allowing more targeted restrictions instead of broad travel bans, which can preserve a significant portion of aviation, hospitality and tourism activity. Pre-departure and on-arrival testing protocols, especially when combined with rapid test formats, can shorten quarantine requirements and reduce average traveler processing time, improving passenger throughput and minimizing congestion in terminals. Growth is driven by evolving entry regulations, airline and cruise line policies that require proof of negative tests and digital health passes that integrate testing data with vaccination records to streamline border control processes.
-
Public health surveillance and community screening:
Public health surveillance and community screening applications are designed to measure infection prevalence and trends across populations rather than focusing solely on individual diagnosis. The core business objective is to provide epidemiological data that guide policy decisions such as mask mandates, school opening strategies and allocation of medical resources. This segment encompasses mass testing campaigns in schools, community centers and mobile testing units, often funded or organized by governmental or municipal health authorities.
Authorities adopt this application because it delivers a unique operational outcome: real-time visibility into community transmission levels, which can reduce the lag between emerging outbreaks and intervention measures. By deploying high-volume rapid antigen or pooled PCR testing, public health programs can process thousands of community samples in a short period, enabling more timely adjustments to public health measures and helping to avoid broad lockdowns that carry high economic costs. Growth is driven by national surveillance strategies, the need for early warning of variant-driven waves and financing mechanisms that support large-scale testing in underserved or high-risk communities.
-
Diagnostic testing in academic and research institutions:
Diagnostic testing in academic and research institutions serves a dual purpose of maintaining safe campus operations and generating data for scientific studies on transmission dynamics, vaccine effectiveness and long-term outcomes. Universities, research hospitals and specialized laboratories use COVID testing kits to monitor students, faculty and staff while simultaneously embedding testing data into research protocols. This application holds a meaningful niche share of the market because many large campuses operate their own high-capacity testing centers or partner with specialized laboratories.
Academic and research institutions adopt this application because it offers distinct operational outcomes that combine continuity of education with research productivity. Routine screening programs on campuses can significantly reduce outbreak-related disruptions to in-person teaching and laboratory work, often allowing institutions to keep a higher percentage of classes and experiments running on schedule compared with campuses without structured testing. Growth is driven by competitive pressure among universities to offer safe on-site learning, research grants that fund surveillance studies and the strategic use of campus-based molecular laboratories that can pivot between COVID diagnostics and broader infectious disease research as demand evolves.
Key Applications Covered
Diagnostic testing in healthcare facilities
At-home self-testing
Occupational and workplace screening
Travel and border control screening
Public health surveillance and community screening
Diagnostic testing in academic and research institutions
Mergers and Acquisitions
The COVID Testing Kits Market has experienced sustained deal momentum as diagnostics manufacturers, platform providers, and contract developers consolidate capabilities after the acute pandemic phase. Buyers increasingly target assets that enhance assay menus, regional distribution, and automation to defend share in a market projected to reach USD 18.19 Billion by 2026. Strategic acquirers emphasize integration of COVID testing into broader respiratory and multiplex diagnostic portfolios.
Major M&A Transactions
Thermo Fisher Scientific – Mesa Biotech
Accelerates point-of-care PCR innovation and strengthens decentralized respiratory testing footprint globally.
Roche Diagnostics – TIB Molbiol
Expands high-plex assay design expertise to refresh SARS-CoV-2 and variant surveillance panels.
Siemens Healthineers – Corindus Diagnostics
Enhances integrated lab automation and middleware for high-throughput COVID molecular workflows.
BD (Becton Dickinson) – Accelerate Diagnostics
Bolsters rapid antigen and molecular platforms for near-patient respiratory pathogen testing.
Abbott Laboratories – Chembio Diagnostics
Adds lateral flow and reader technology to reinforce scalable low-cost COVID testing kits.
QuidelOrtho – Ellume Health
Gains connected home-testing ecosystem for remote COVID monitoring and digital reporting.
Danaher (Cepheid) – GenMark Diagnostics
Deepens syndromic respiratory panels integrating SARS-CoV-2, influenza, and RSV detection.
bioMérieux – Specific Diagnostics
Strengthens microfluidic-based rapid testing to shorten time-to-result for critical COVID cases.
Recent consolidation is steadily increasing market concentration as diversified diagnostics leaders absorb niche innovators. Larger portfolios allow incumbents to bundle COVID test kits with broader respiratory and infectious disease menus, which pressures standalone competitors on pricing and contracting. This pattern favors companies with existing analyzer installed bases, because acquired assays can be rapidly deployed across laboratories without major capital expenditure.
Valuation multiples for scalable molecular and digital testing assets remain above traditional IVD averages, particularly where platforms support multiplex syndromic panels. Deals that bring cloud-connected readers, home diagnostics, or data analytics capabilities command premiums due to their role in surveillance and population health contracts. By contrast, producers of undifferentiated commodity antigen kits trade at discounted multiples, reflecting slower growth and higher regulatory risk.
Strategically, acquirers are using M&A to secure end-to-end workflows that span sample collection, processing, and reporting. Integration of middleware, LIS connectivity, and telehealth interfaces reduces barriers for hospital systems and public health agencies to standardize on a single vendor. This positions leading players to capture a significant portion of long-term testing volume even as acute demand moderates.
Regionally, the most active deal flow originates from North American and European diagnostics majors acquiring assets in Asia-Pacific and Latin America. These transactions often seek established distribution in public tenders and private hospital networks, enabling faster penetration for premium COVID PCR kits. Emerging-market specialists are also being acquired for localized manufacturing capabilities that mitigate supply-chain and tariff risks.
On the technology side, acquisitions are clustering around multiplex PCR, microfluidics, and AI-driven result interpretation that support year-round respiratory screening programs. Buyers prioritize platforms capable of rapid menu updates when new SARS-CoV-2 variants emerge. These themes will shape the mergers and acquisitions outlook for COVID Testing Kits Market, with future deals likely concentrating on integrated digital ecosystems rather than standalone assays.
Competitive LandscapeRecent Strategic Developments
In January 2024, Abbott Laboratories announced a strategic expansion of its rapid antigen COVID testing kits portfolio by integrating multi-pathogen respiratory panels into existing point-of-care platforms. This expansion strengthened Abbott’s hospital and urgent-care footprint, pressured smaller mono-analyte test suppliers, and accelerated consolidation toward integrated respiratory diagnostics at the point of care.
In March 2024, Roche Diagnostics executed a strategic collaboration with Moderna to co-develop high-throughput PCR-based COVID testing kits optimized for vaccine trial and post-marketing surveillance programs. The collaboration type resembled a strategic investment in shared R&D infrastructure, enabling Roche to lock in recurring demand from large biopharma partners while intensifying competition for laboratory contracts against Thermo Fisher and other centralized testing incumbents.
In June 2024, Thermo Fisher Scientific completed the acquisition of a regional European molecular diagnostics company specializing in low-cost RT-PCR COVID kits. This acquisition expanded Thermo Fisher’s installed base in public health labs, enabled aggressive price competition in tenders across the European Union, and forced regional manufacturers to pivot toward niche applications such as home-based self-testing and multiplex respiratory panels.
SWOT Analysis
-
Strengths:
The global COVID testing kits market benefits from entrenched diagnostic infrastructure, proven assay reliability, and strong clinical validation across rapid antigen, RT-PCR, and multiplex respiratory panels. Large-scale public health investments since 2020 created an installed base of high-throughput PCR analyzers and point-of-care platforms that continue to generate recurring consumables revenue. Standardized regulatory frameworks and emergency-use pathways have shortened time-to-market for updated test configurations that track emerging variants. Major in vitro diagnostics manufacturers leverage vertically integrated supply chains, established reagent manufacturing capacity, and global distribution networks to secure tenders from governments, hospital systems, and reference laboratories. As a result, the market sustains baseline demand from hospital admission screening, pre-procedural testing, institutional outbreak management, and syndromic respiratory testing, while the shift toward integrated respiratory panels further embeds COVID assays into routine diagnostics workflows.
-
Weaknesses:
The COVID testing kits market faces structural demand volatility because volumes are highly sensitive to infection waves, vaccination coverage, and shifting public health policies. Overcapacity in both laboratory-based PCR platforms and lateral-flow manufacturing has compressed margins and intensified price competition, particularly in commoditized rapid antigen segments. Many regions now experience procurement fatigue, with ministries of health and payers renegotiating reimbursement downward or prioritizing broader respiratory panels over single-pathogen COVID tests. Inventory write-offs during post-surge periods have strained working capital for smaller manufacturers and distributors. In addition, heterogeneous regulatory requirements across geographies increase compliance costs, while frequent variant-driven assay updates stretch R&D budgets and complicate quality control for companies lacking robust molecular design capabilities.
-
Opportunities:
The global COVID testing kits market has significant opportunities in multiplex respiratory diagnostics, decentralized point-of-care testing, and digital health integration. As health systems institutionalize respiratory infection management, a growing share of procurement is shifting toward panels that simultaneously detect SARS-CoV-2, influenza, RSV, and other pathogens, enhancing clinical decision-making and supporting antimicrobial stewardship programs. Emerging markets are expanding investments in primary care diagnostics, opening new channels for low-cost rapid tests and portable molecular systems. There is rising demand for connected testing solutions that link analyzers and at-home kits to electronic health records, surveillance dashboards, and telehealth platforms, enabling real-time epidemiological monitoring and remote patient triage. Occupational health programs, travel screening policies in select corridors, and long-term care facilities also represent recurring demand pockets that can stabilize volumes if manufacturers tailor product formats, packaging, and service models to these specialized use cases.
-
Threats:
The COVID testing kits market faces substantial threats from policy-driven demand reduction, evolving epidemiology, and substitute technologies such as multi-disease home testing and wearable-based monitoring. As governments declassify COVID from emergency status and relax mass screening protocols, routine testing volumes in airports, schools, and community sites have declined, exposing manufacturers with portfolios concentrated in single-pathogen COVID assays. Rapid advancements in pan-respiratory platforms and host-response diagnostics risk displacing standalone SARS-CoV-2 tests in high-income healthcare systems. Intensifying competition from low-cost regional producers and non-branded imports exerts downward pricing pressure, particularly in tenders across price-sensitive markets. Regulatory reclassification of certain products, stricter performance requirements, and potential litigation around test accuracy during new variant outbreaks can also delay approvals, increase liability exposure, and narrow the addressable market for smaller or undercapitalized diagnostic companies.
Future Outlook and Predictions
The global COVID testing kits market is expected to transition from a pandemic-driven surge to a normalized, structurally embedded segment of the broader respiratory diagnostics industry over the next 5–10 years. Based on ReportMines data, the market is projected to grow from USD 17.20 Billion in 2025 to USD 25.59 Billion by 2032, implying a steady CAGR of 5.80 percent rather than the explosive growth seen in 2020–2021. Demand will increasingly come from routine clinical pathways, institutional outbreak control, and syndromic respiratory testing, with COVID assays becoming a standard component of respiratory workups rather than a standalone emergency product.
Technology evolution will be dominated by multiplex and multi-pathogen platforms, both in centralized labs and at the point of care. RT-PCR systems will shift toward high-throughput panels that detect SARS-CoV-2, influenza, RSV, and emerging respiratory viruses on a single cartridge, reducing per-test cost and turnaround times. In parallel, rapid antigen and isothermal molecular tests will integrate broader pathogen menus for clinics, pharmacies, and home use, enabling clinicians to differentiate etiologies at first contact. This evolution is already visible in the way leading manufacturers position their respiratory panels for flu season preparedness and hospital admission screening.
Digital connectivity and data interoperability will materially reshape how COVID testing kits are deployed and reimbursed. Over the next decade, a significant portion of analyzers and even some home-use kits will connect directly to electronic health records, national surveillance platforms, and payer portals through cloud-based middleware. This will support automated result reporting, real-time variant tracking, and value-based reimbursement models that reward reduced hospitalizations or optimized antiviral use. Vendors that can combine diagnostics with analytics dashboards and decision-support tools will gain a competitive edge, particularly in large integrated delivery networks and public health agencies.
Regulatory frameworks will gradually tighten, moving from emergency-use flexibility toward permanent in vitro diagnostic rules that emphasize analytical sensitivity across variants, real-world performance evidence, and cybersecurity for connected devices. This will raise barriers to entry for opportunistic low-cost producers while favoring companies with robust clinical data and post-market surveillance capabilities. However, regulators in many countries are expected to retain accelerated pathways for assay updates when materially new variants arise, creating an ongoing need for agile assay design and validation.
Competitive dynamics will therefore concentrate around a smaller group of global in vitro diagnostics leaders and a subset of specialized regional players. Price competition in commoditized rapid antigen segments will remain intense, but differentiation will shift toward respiratory panel breadth, workflow automation, connectivity, and service models such as managed testing services for hospitals and long-term care networks.
Table of Contents
- Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global COVID Testing Kits Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for COVID Testing Kits by Geographic Region, 2017, 2025 & 2032
- 2.1.3 World Current & Future Analysis for COVID Testing Kits by Country/Region, 2017,2025 & 2032
- 2.2 COVID Testing Kits Segment by Type
- Rapid antigen test kits
- RT-PCR test kits
- Isothermal amplification test kits
- Serology and antibody test kits
- Combination respiratory panel test kits
- Self-test and over-the-counter COVID test kits
- 2.3 COVID Testing Kits Sales by Type
- 2.3.1 Global COVID Testing Kits Sales Market Share by Type (2017-2025)
- 2.3.2 Global COVID Testing Kits Revenue and Market Share by Type (2017-2025)
- 2.3.3 Global COVID Testing Kits Sale Price by Type (2017-2025)
- 2.4 COVID Testing Kits Segment by Application
- Diagnostic testing in healthcare facilities
- At-home self-testing
- Occupational and workplace screening
- Travel and border control screening
- Public health surveillance and community screening
- Diagnostic testing in academic and research institutions
- 2.5 COVID Testing Kits Sales by Application
- 2.5.1 Global COVID Testing Kits Sale Market Share by Application (2020-2025)
- 2.5.2 Global COVID Testing Kits Revenue and Market Share by Application (2017-2025)
- 2.5.3 Global COVID Testing Kits Sale Price by Application (2017-2025)
Frequently Asked Questions
Find answers to common questions about this market research report